BackZymeworks BC Overview

Zymeworks BC Other Assets

Latest other assets for ZYME: $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer trimmed avg / median

Loading

Zymeworks BC Other Assets History

Loading

Zymeworks BC vs. peers: Other Assets Comparison

Loading

Zymeworks BC Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zymeworks BC (ZYME) FAQ

Zymeworks BC (ZYME) currently reports a other assets of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Zymeworks BC's other assets history and peer comparisons.

Zymeworks BC's other assets changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zymeworks BC reported $0 in other assets as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other assets of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zymeworks BC, and consider following ZYME for alerts when major investors trade the stock.

Zymeworks BC is classified in the Healthcare sector. On other assets, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZYME with unrelated industries.